Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized trial of ZOC2019619 eye drops versus timolol in primary open-angle glaucoma or ocular hypertension
CTR20262894Phase 3Active
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Jul 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ZOC2019619 in open-angle glaucoma (OAG), ocular hypertension, sponsored by Zhongshan Ophthalmic Center. Started Jul 2026; status: active.
02
Drugs
ZOC2019619
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on CTR20262894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262894.